4-aminopyridine has been researched along with Lymphoma, B-Cell in 1 studies
Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Mouse oral bioavailability was complete (100%) with extensive tumor exposure." | 1.43 | The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma. ( Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Henley, AT; Hunter, JE; Lainchbury, M; Matthews, TP; McHardy, T; Osborne, J; Perkins, ND; Raynaud, FI; Reader, JC; Swales, K; Tall, M; Valenti, MR; Walton, MI, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Walton, MI | 1 |
| Eve, PD | 1 |
| Hayes, A | 1 |
| Henley, AT | 1 |
| Valenti, MR | 1 |
| De Haven Brandon, AK | 1 |
| Box, G | 1 |
| Boxall, KJ | 1 |
| Tall, M | 1 |
| Swales, K | 1 |
| Matthews, TP | 1 |
| McHardy, T | 1 |
| Lainchbury, M | 1 |
| Osborne, J | 1 |
| Hunter, JE | 1 |
| Perkins, ND | 1 |
| Aherne, GW | 1 |
| Reader, JC | 1 |
| Raynaud, FI | 1 |
| Eccles, SA | 1 |
| Collins, I | 1 |
| Garrett, MD | 1 |
1 other study available for 4-aminopyridine and Lymphoma, B-Cell
| Article | Year |
|---|---|
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Topics: 4-Aminopyridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; C | 2016 |